Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 310.4
(-0.06%)
SEK 310.4
(-0.06%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 14.05 Billion SEK | 0.28% |
| 2022 | 14.01 Billion SEK | 16.35% |
| 2021 | 12.04 Billion SEK | 0.07% |
| 2020 | 12.03 Billion SEK | 10.29% |
| 2019 | 10.91 Billion SEK | 62.31% |
| 2018 | 6.72 Billion SEK | 44.38% |
| 2017 | 4.65 Billion SEK | 27.57% |
| 2016 | 3.65 Billion SEK | 81.9% |
| 2015 | 2 Billion SEK | 29.66% |
| 2014 | 1.54 Billion SEK | 20.55% |
| 2013 | 1.28 Billion SEK | 23.41% |
| 2012 | 1.04 Billion SEK | 6.75% |
| 2011 | 974.57 Million SEK | -20.18% |
| 2010 | 1.22 Billion SEK | 32.54% |
| 2009 | 921.23 Million SEK | 5.17% |
| 2008 | 875.92 Million SEK | -3.5% |
| 2007 | 907.65 Million SEK | 0.04% |
| 2006 | 907.29 Million SEK | 36.24% |
| 2005 | 665.94 Million SEK | 67.76% |
| 2004 | 396.96 Million SEK | -62.03% |
| 2003 | 1.04 Billion SEK | 48.32% |
| 2002 | 704.82 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 4.7 Billion SEK | 5.56% |
| 2024 Q2 | 3.29 Billion SEK | -30.04% |
| 2024 Q3 | 5.56 Billion SEK | 68.93% |
| 2023 Q2 | 3.5 Billion SEK | -16.11% |
| 2023 Q4 | 4.45 Billion SEK | 11.48% |
| 2023 Q3 | 4 Billion SEK | 14.29% |
| 2023 Q1 | 4.17 Billion SEK | -10.89% |
| 2023 FY | 14.05 Billion SEK | 0.28% |
| 2022 Q3 | 3.06 Billion SEK | 7.39% |
| 2022 Q4 | 4.68 Billion SEK | 52.66% |
| 2022 Q2 | 2.85 Billion SEK | -16.22% |
| 2022 FY | 14.01 Billion SEK | 16.35% |
| 2022 Q1 | 3.4 Billion SEK | -12.14% |
| 2021 Q1 | 2.93 Billion SEK | -21.06% |
| 2021 Q4 | 3.88 Billion SEK | 38.47% |
| 2021 Q3 | 2.8 Billion SEK | 15.4% |
| 2021 Q2 | 2.42 Billion SEK | -17.27% |
| 2021 FY | 12.04 Billion SEK | 0.07% |
| 2020 Q3 | 2.33 Billion SEK | -1.81% |
| 2020 Q1 | 3.59 Billion SEK | -6.16% |
| 2020 Q2 | 2.38 Billion SEK | -33.81% |
| 2020 FY | 12.03 Billion SEK | 10.29% |
| 2020 Q4 | 3.71 Billion SEK | 59.02% |
| 2019 Q3 | 2.17 Billion SEK | -9.95% |
| 2019 Q4 | 3.83 Billion SEK | 76.39% |
| 2019 FY | 10.91 Billion SEK | 62.31% |
| 2019 Q1 | 2.49 Billion SEK | 31.72% |
| 2019 Q2 | 2.41 Billion SEK | -3.25% |
| 2018 FY | 6.72 Billion SEK | 44.38% |
| 2018 Q3 | 1.74 Billion SEK | 3.82% |
| 2018 Q2 | 1.67 Billion SEK | 18.77% |
| 2018 Q4 | 1.89 Billion SEK | 8.76% |
| 2018 Q1 | 1.41 Billion SEK | 5.62% |
| 2017 FY | 4.65 Billion SEK | 27.57% |
| 2017 Q4 | 1.33 Billion SEK | 18.51% |
| 2017 Q3 | 1.12 Billion SEK | -3.09% |
| 2017 Q2 | 1.16 Billion SEK | 13.23% |
| 2017 Q1 | 1.02 Billion SEK | 19.6% |
| 2016 FY | 3.65 Billion SEK | 81.9% |
| 2016 Q3 | 782 Million SEK | -26.57% |
| 2016 Q1 | 944 Million SEK | 81.23% |
| 2016 Q2 | 1.06 Billion SEK | 12.82% |
| 2016 Q4 | 859.51 Million SEK | 9.91% |
| 2015 Q3 | 486 Million SEK | 0.83% |
| 2015 FY | 2 Billion SEK | 29.66% |
| 2015 Q1 | 519 Million SEK | 21.66% |
| 2015 Q4 | 520.89 Million SEK | 7.18% |
| 2015 Q2 | 482 Million SEK | -7.13% |
| 2014 Q4 | 426.6 Million SEK | 7.92% |
| 2014 FY | 1.54 Billion SEK | 20.55% |
| 2014 Q3 | 395.3 Million SEK | -2.68% |
| 2014 Q2 | 406.2 Million SEK | 27.06% |
| 2014 Q1 | 319.7 Million SEK | -10.74% |
| 2013 Q2 | 316.7 Million SEK | 4.56% |
| 2013 Q1 | 302.9 Million SEK | 13.28% |
| 2013 Q4 | 358.16 Million SEK | 16.97% |
| 2013 FY | 1.28 Billion SEK | 23.41% |
| 2013 Q3 | 306.2 Million SEK | -3.32% |
| 2012 Q3 | 266.6 Million SEK | 7.98% |
| 2012 Q4 | 267.37 Million SEK | 0.29% |
| 2012 FY | 1.04 Billion SEK | 6.75% |
| 2012 Q1 | 259.4 Million SEK | 43.98% |
| 2012 Q2 | 246.9 Million SEK | -4.82% |
| 2011 Q2 | 276.5 Million SEK | -2.61% |
| 2011 Q3 | 234 Million SEK | -15.37% |
| 2011 FY | 974.57 Million SEK | -20.18% |
| 2011 Q4 | 180.17 Million SEK | -23.0% |
| 2011 Q1 | 283.9 Million SEK | -9.36% |
| 2010 FY | 1.22 Billion SEK | 32.54% |
| 2010 Q1 | 313.1 Million SEK | 22.82% |
| 2010 Q2 | 309.5 Million SEK | -1.15% |
| 2010 Q4 | 313.2 Million SEK | 9.82% |
| 2010 Q3 | 285.2 Million SEK | -7.85% |
| 2009 Q3 | 183.2 Million SEK | -23.86% |
| 2009 Q1 | 242.5 Million SEK | 0.0% |
| 2009 Q4 | 254.93 Million SEK | 39.16% |
| 2009 FY | 921.23 Million SEK | 5.17% |
| 2009 Q2 | 240.6 Million SEK | -0.78% |
| 2008 FY | 875.92 Million SEK | -3.5% |
| 2007 FY | 907.65 Million SEK | 0.04% |
| 2006 FY | 907.29 Million SEK | 36.24% |
| 2005 FY | 665.94 Million SEK | 67.76% |
| 2004 FY | 396.96 Million SEK | -62.03% |
| 2003 FY | 1.04 Billion SEK | 48.32% |
| 2002 FY | 704.82 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | -213082.646% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | 2952410.924% |
| BioGaia AB (publ) | 950.19 Million SEK | -1378.967% |
| Enzymatica AB (publ) | 31.86 Million SEK | -44004.447% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | 360340.964% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | 156144544.444% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | 669609.29% |
| Nanexa AB (publ) | 59.15 Million SEK | -23655.43% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | -87550.471% |
| ODI Pharma AB | -1.34 Million SEK | 1047553.294% |
| Orexo AB (publ) | 549.9 Million SEK | -2455.556% |
| Probi AB (publ) | 220.21 Million SEK | -6281.549% |
| Swedencare AB (publ) | 164.8 Million SEK | -8427.306% |
| Toleranzia AB | -919 Thousand SEK | 1529262.133% |
| Vivesto AB | -10.65 Million SEK | 131978.754% |